Medicube PDRN Pink Peptide Eye Cream (30ml)
1,500.0৳
A revitalizing eye treatment formulated with PDRN and a triple peptide complex to brighten and firm the delicate eye area. This high-performance cream targets dark circles and fine lines to restore a youthful, energized look.
Add 999.0৳ to cart and get free shipping!
Medicube PDRN Pink Peptide Eye Cream (30ml)
Features
- Contains high-purity Salmon-derived PDRN for skin regeneration
- Infused with a Triple Pink Peptide complex for intensive firming
- Clinically tested for sensitive skin around the eyes
- 30ml concentrated formula for long-lasting use
- Non-greasy and fast-absorbing texture
Benefits
- Visibly brightens stubborn dark circles and discoloration
- Reduces the appearance of fine lines and crow’s feet
- Improves skin elasticity and prevents sagging
- Provides deep hydration to the delicate orbital area
- Soothes puffiness for a refreshed morning appearance
How to Use
- Cleanse your face and apply toner first
- Dispense a small, pea-sized amount onto your ring finger
- Gently tap the cream around the orbital bone and under-eye area
- Avoid direct contact with the eyes
- Use twice daily in the morning and evening for best results
Description
This innovative eye cream leverages the regenerative power of PDRN. PDRN is a DNA-derived ingredient known for its ability to repair skin tissue. The formula is enhanced with a specialized Pink Peptide complex. These peptides work synergistically to boost collagen production. It effectively targets the root causes of dark circles. The cream creates a moisture barrier to prevent dehydration lines. Regular use leads to a firmer and more luminous eye contour. It is suitable for all skin types including sensitive skin.
Ingredients
Water, Glycerin, Butylene Glycol, Niacinamide, Salmon DNA (PDRN), Palmitoyl Tripeptide-5, Acetyl Hexapeptide-8, Copper Tripeptide-1, Adenosine, Sodium Hyaluronate, Panthenol, Allantoin, Ethylhexylglycerin, Caprylyl Glycol, 1,2-Hexanediol, Cyanocobalamin, Disodium EDTA

Reviews
There are no reviews yet.